NCT06994806View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2028

Conditions
Solid Tumor Malignancies
Interventions
DRUG

KQB168

Oral KQB168

DRUG

Pembrolizumab

Intravenous pembrolizumab

Trial Locations (4)

22031

RECRUITING

NEXT Virginia, Fairfax

77054

RECRUITING

NEXT Huston, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

78758

RECRUITING

NEXT Austin, Austin

Sponsors
All Listed Sponsors
lead

Kumquat Biosciences Inc.

INDUSTRY

NCT06994806 - A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter